Clinical Trial

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

Name: A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) — clinical trial record (NCT07592689)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend

Protocol Amendment History 2 changes

notable Trial sites expanded: 27 -> 32 locations 2026-07-30

notable Trial sites expanded: 18 -> 27 locations 2026-05-28

Trial Details

NCT Number	NCT07592689
Lead Sponsor	Definium Therapeutics US, Inc.
Conditions	Major Depressive Disorder
Enrollment	165 participants
Start Date	2026-05-10
Primary Completion	2027-09 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2026-08-10